Bempedoic acid 180 MG / ezetimibe 10 MG Oral Tablet — RxCUI 2283230
RxNorm drug concept · Semantic clinical drug
RxCUI 2283230
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2283230
Official nameBempedoic acid 180 MG / ezetimibe 10 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)15,360 prescriptions · 31 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Ezetimibe: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It lowers LDL cholesterol along with a healthy diet. You may take it alone or with a statin or fenofibrate. It is also used for some inherited cholesterol conditions.
- For Zetia, take it as soon as you remember. Do not double up on the next dose. If you are unsure, ask me or your prescriber.
- What happens if I miss a dose of ezetimibe?
- You can take it with or without food. If you also take a bile acid sequestrant like cholestyramine, take ezetimibe at least 2 hours before or 4 hours after it.
🕸️ Concept Web — How Bempedoic acid 180 MG / ezetimibe 10 MG Oral Tab... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Bempedoic acid 180 MG / ezetimibe 10 MG Oral Tablet
RxCUI 2283230 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 3
The active substance itself — no strength, form, or brand attached yet.
-
Bempedoic acid
2282403IN -
Ezetimibe
341248IN -
Bempedoic acid / ezetimibe
2283229MIN
-
Bempedoic acid
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Nexlizet
2283231BN
-
Nexlizet
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Bempedoic acid / ezetimibe Oral Tablet
2283228SCDF -
Bempedoic acid / ezetimibe Oral Product
2283226SCDG -
Bempedoic acid / ezetimibe Pill
2283227SCDG -
Bempedoic acid / ezetimibe Oral Tablet [Nexlizet]
2283233SBDF -
Nexlizet Oral Product
2283234SBDG -
Nexlizet Pill
2283235SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Bempedoic acid / ezetimibe Oral Tablet
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Bempedoic acid 180 MG
2282404SCDC -
Ezetimibe 10 MG
350671SCDC -
Bempedoic acid 180 MG / ezetimibe 10 MG Oral Tablet [Nexlizet]
2283236SBD -
Bempedoic acid 180 MG / ezetimibe 10 MG [Nexlizet]
2283232SBDC
-
Bempedoic acid 180 MG
Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Bempedoic acid 180 MG
SCDC · 2282404 -
Ezetimibe 10 MG
SCDC · 350671 -
Bempedoic acid / ezetimibe Oral Tablet
SCDF · 2283228 -
Bempedoic acid / ezetimibe Oral Product
SCDG · 2283226 -
Bempedoic acid / ezetimibe Pill
SCDG · 2283227
Brand-Name Concepts
-
Bempedoic acid 180 MG / ezetimibe 10 MG Oral Tablet [Nexlizet]
SBD · 2283236 -
Bempedoic acid 180 MG / ezetimibe 10 MG [Nexlizet]
SBDC · 2283232 -
Bempedoic acid / ezetimibe Oral Tablet [Nexlizet]
SBDF · 2283233 -
Nexlizet Oral Product
SBDG · 2283234 -
Nexlizet Pill
SBDG · 2283235 -
Nexlizet
BN · 2283231
📦 FDA Products & Package NDCs
1 product · 2 package NDCs
2 package NDCs map to RxCUI 2283230 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 72426-0818-03 | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72426-818-03) | Nexlizet | Esperion Therapeutics, Inc. | 2020-03-09 |
| 72426-0818-99 | 7 TABLET, FILM COATED in 1 BLISTER PACK (72426-818-99) | Nexlizet | Esperion Therapeutics, Inc. | 2020-03-09 |
Observed labelers:
Esperion Therapeutics, Inc. (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$13.8180
Range $13.8180–$13.8180
· middle 50% $13.8180–$13.8180
· 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.